Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Laser Focal Therapy of Intermediate Risk Localized Prostate Cancer

NCT03373006 is registered in ClinicalTrials.gov with HALO Diagnostics as lead sponsor.

NCT NCT03373006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03373006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Laser Focal Therapy of Intermediate Risk Localized Prostate Cancer
Lead sponsor
HALO Diagnostics
Phase
Phase 2
Overall status
Completed
Start date
February 27, 2018
Completion date
January 30, 2020
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer